Prozac (fluoxetine) is from a class of medicines called SSRIs (selective serotonin reuptake inhibitors). Usually the drug is used to treat depression, obsessive-compulsive disorder, some eating disorders, and panic attacks. It is also used off-label to treat fatigue in multiple sclerosis (MS). Fluoxetine may need to be taken for several weeks…
Search results for:
I thought I’d finish writing this last night, but I was too tired. Same thing the night before, and I’m sure this sounds familiar to a lot of you. The National Multiple Sclerosis Society estimates about 80% of the people who have MS have fatigue as one of…
Prozac (fluoxetine) is used to treat depression, obsessive-compulsive disorder, panic attacks, and some eating disorders. Prozac is an antidepressant from the selective serotonin reuptake inhibitors (SSRIs) group. In a positive way, it effects chemicals in the brain that may be unbalanced in people with depression, anxiety, or similar…
Urinary incontinence is believed to have a greater social impact than any other multiple sclerosis (MS) symptom or complication when it comes to quality of life. It discourages people from engaging in outdoor activities and affects their ability to work. While the symptom can be caused by urinary tract infections, which are common…
Paxil (paroxetine) is used to treat depression and some types of anxiety. It is an antidepressant from the selective serotonin reuptake inhibitors (SSRIs) group. Paxil makes a positive affect on chemicals in the brain that may be unbalanced in people with depression, anxiety, or similar conditions. Because depression is a common…
Depression is a common and well documented symptom of multiple sclerosis. Effexor XR (venlafaxine) belongs to a group of medications called selective serotonin and norepinephrine reuptake inhibitors (SSNRI). The drug increases serotonin and norepinephrine, which are natural substances that positively affect communication between nerve cells or restore chemical balances in the brain. The…
Ciprofloxacin is a fluoroquinolone antibiotic that fights bacteria in the body. It is used to treat different types of bacterial infections. In MS patients, it is used to treat urinary tract infections. The bactericidal action of ciprofloxacin results from interference with theDNA gyrase, and essential bacterial enzyme that bacteria…
Multiple sclerosis patients often have bladder disturbances such as an urgent need to urinate, frequent urination, an inability to completely empty the bladder, and sometimes incontinence. A urinary tract infection should always be excluded before starting any medication. Propantheline is an antispasmodic/anticholinergic medicine used to relieve cramps or spasms of…
Flomax (tamsulosin) is an FDA-approved medicine to treat signs and symptoms of benign enlargement of the prostate (benign prostatic hyperplasia), by helping to relax the muscles in the prostate and bladder. It is also prescribed to men with multiple sclerosis who suffer from bladder dysfunction. Bladder disturbances are common in…
The jury is still out on the role, if any, that heavy metals play in multiple sclerosis. Many theories have been floating around for years regarding the possible connection between MS and dental amalgams, pesticides, additives to food, lead paint in older homes … and the list goes on. The National…
Ready to fight MS? Well, you can start first thing every day. So, how do you start your day — a coffee maybe, or a great cup of tea? Tea is my choice but I also enjoy a magnificent cup of Spanish coffee. According to a number of recent studies, coffee and…
News
Adamas Reports Positive Results in Study of Drug to Treat MS Patients with Walking Difficulties
Adamas Pharmaceuticals recently reported positive results from its Phase 2 proof-of-concept clinical trial evaluating ADS-5102 (amantadine HCl), an extended-release version of amantadine, in multiple sclerosis (MS) patients with difficulties in walking. The trial (NCT02471222), a double-blind, placebo-controlled and two-arm parallel group study, evaluated ADS-5102 given once daily at 340 mg, at bedtime, for four…
For those with Multiple Sclerosis, the progressive manner in which the disease slowly deteriorates motor function, balance, and coordination can make home maintenance an impossibility. Add to this the well-documented issues that MS patients have with finding and keeping jobs and very quickly the cost and effort to maintain…
Cambridge, Massachusetts based Genzyme announced Friday that the U.S. Food and Drug Administration (FDA) has approved the company’s new drug Lemtrada (alemtuzumab) for treatment of people with relapsing forms of multiple sclerosis, which includes people who experience periodic MS attacks, such as those who have relapsing-remitting MS or secondary-progressive…
News
Québec Government Covers Lemtrada Second-line Treatment For Relapsing-remitting Multiple Sclerosis
Genzyme, a Sanofi company, has announced that the Canadian province of Québec’s Institut national d’excellence en santé et services sociaux (INESSS) has recommended that the company’s multiple sclerosis (MS) drug Lemtrada (alemtuzumab) 12 mg be included on the provincial drug formulary under “Médicament d’exception” as a second-line treatment for…
The underlying cause of fatigue experienced by multiple sclerosis (MS) patients may be undiagnosed sleep disorders, according to a study conducted at the Department of Neurology of the University of California. Not only is that a problem in itself, but also an undiagnosed and untreated sleeping disorder may exacerbate the…
Magnetic resonance imaging (MRI) can predict responses to depression treatment in patients with multiple sclerosis (MS), according to Anthony Feinstein, Professor at the Department of Psychiatry of the Sunnybrook Health Sciences Centre & the University of Toronto. In the presentation “Depression in MS: Is brain imaging helpful?” at this…
Cambridge, Mass. Based Genzyme, a Sanofi subsidiary, announced May 30 that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s resubmission of its supplemental Biologics License Application (sBLA) seeking approval of its proprietary drug Lemtrada (alemtuzumab) for treatment of relapsing forms of multiple sclerosis (MS).